Status:
TERMINATED
Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial)
Lead Sponsor:
Alice K. Gong
Conditions:
Infantile Hemangioma
Very Low Birth Weight Infants
Eligibility:
All Genders
Up to 6 years
Phase:
PHASE1
Brief Summary
The purpose of this trial is to see if a topical beta blocker is effective in preventing the proliferation of infantile hemangioma.
Detailed Description
Infantile hemangiomas (IH) are among the most common, benign vascular tumors of infancy with an estimated prevalence of 4-5% of the population. IH are not found at birth but become evident within the ...
Eligibility Criteria
Inclusion
- Babies admitted to NICU or seen in follow clinic that have a diagnosis of hemangioma that is verified by Principal Investigator (PI) or Co-Principal Investigators.
Exclusion
- Babies with PHACES (Posterior fossa, Hemangioma, Arterial lesions, Cardiac abnormalities, Eye abnormalities) syndrome
- Babies with cardiac conditions that may predispose to heart block
- Babies with persistent hypoglycemia
- Babies on medications that may interact with beta blockers
- Babies who are hemodynamically unstable and are requiring pressors to maintain blood pressure
- Babies who are on systemic corticosteroid therapy
Key Trial Info
Start Date :
July 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2016
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT01434849
Start Date
July 1 2012
End Date
April 1 2016
Last Update
November 15 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States, 78229-3900